Unity Biotechnology, Inc.

Unity Biotechnology, Inc. (NASDAQ: UBX) is a clinical-stage biotechnology company. It develops and commercializes therapeutics for the treatment of ageing.

Key Highlights

• UBX is a loss-making entity as of Q3FY21 (ended September 30, 2021) and has yet to generate any revenues.
• It exited the quarter with total cash and cash equivalents (including marketable securities) of USD 88.5 million, which it believes is sufficient to fund operations through Q3FY22.
• The stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, and its RSI Index is at an RSI level of 38.15.
• It is leaning towards the lower end of its 52-week range of USD 1.54 to USD 9.78.
• UBX's stock price fell 69.59% in the past twelve months.

Technical Price Chart (as of December 09, 2021). Analysis by Kalkine

Conclusion: Considering the lackluster fundamentals, adequate liquidity, and other technical indicators, we recommend a "Watch" rating on the stock at the current price of USD 1.87, down 4.10%, as of December 09, 2021, 12:11 PM ET.

*The reference data in this report has been partly sourced from REFINITIV. 

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.